Advances in the treatment of pancreatic cancer: Limitations of surgery and evaluation of new therapeutic strategies

摘要: Pancreatic ductal carcinoma is one of the most dismal malignancies gastrointestinal system. Even after curative resection, actual 5-year survival only 10%–20%. Of all treatments used against pancreatic cancer, surgery still that can achieve complete cure. cancer spreads easily to adjacent tissues and distant metastasis common. Typically, this invades retropancreatic neural tissue, duodenum, portal vein (PV), superior mesenteric (SMV), or regional lymph nodes. For reason, aggressive removes cancerous lesion completely recommended. Several retrospective prospective studies have been conducted validate usefulness for in past few decades. Surprisingly, benefits denied by randomized controlled trials (RCTs). This implies alone not enough. Thus, adjuvant therapy, such as radiotherapy chemotherapy, has given combination with improve survival. Although are limited, results chemotherapy promising. Other newly evolving molecular targeting drugs may also treatment outcomes cancer.